// App-Quantinova.ai

: Trends in the Use of Hematopoietic Stem Cell Transplantation in the Management of Relapsed/Refractory Diffuse Large B Cell Lymphoma. a Retrospective Analysis of the Lymphoma Working Party of the EBMT

Researchers

Presenter

  • Anna Sureda

Principal Investigators

  • Ariane Boumendil

  • Philipp Berning

  • Herve Finel

  • Denis Caillot

  • Wolf Roesler

  • Jurgen Finke

  • Igor Wolfgang Blau

  • Veronique Leblond

  • Joerg Bittenbring

  • Anna Tsoulkani

  • Ben Carpenter

  • Arnon Nagler

  • Didier Blaise

  • Peter Dreger

  • Norbert Schmitz

Medical Centers

  • Dept. Hematology, Oncology and Tumorimmunology, Charité University Medicine Berlin, Berlin, Germany

  • Department of Medicine A, University Hospital Münster, Münster, Germany

  • Department of Medicine, Hematology-Oncology, University of Freiburg, Freiburg, Germany

  • Department of Hematology and Oncology, Saarland University Medical School, Homburg, Germany

  • Internal Medicine V - Hematology, Oncology & Rheumatology, University of Heidelberg, Heidelberg, Germany

  • Hematology Department, Dijon University Hospital, Dijon, France

  • University College London Hospital, Department of Haematology, London, United Kingdom

  • EBMT Lymphoma Working Party Paris Office, Paris, France

  • Hematology Department, Institut Català d'Oncologia-Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain

  • University of Erlangen-Nuernberg - Hematology/Oncology, Erlangen, Germany

  • Hematology Department, Institut Paoli-Calmettes, Marseille, France

  • NOTTINGHAM UNIVERSITY, Nottingham, United Kingdom

  • Département d’ Hématologie Hôpital Pitié-Salpêtrière APHP, UPMC Université Paris, Paris, France

  • Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel

Locations

  • Germany

  • France

  • United Kingdom

  • Spain

  • Israel

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Allopurinol

Outcome

  • N/A


Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A